In addition, a retrospective study using ICIs to treat NSCLC patients showed that the increased PD-L1 level in macrophages was associated with a better survival chance, suggesting that the PD-L1 level in the macrophages might be used to predict the ICI treatment response.[9] The study result should be confirmed. This evidence concerns the gene CD274 and non-small cell lung carcinoma.